Mark Fogg, Ph.D.

Group Leader Immunology at Abzena

Speaker

Mark Fogg, Ph.D., leads the Immunology Group at Abzena, a company that enables the development and manufacture of better biopharmaceuticals. Mark obtained his PhD in T cell immunology at the University of Reading, and carried out his postdoctoral work on the generation of T cells for cancer immunotherapy at Harvard Medical School. He then migrated to industry to lead a cell biomarker discovery group within Pfizer BioTX R&D prior to joining Abzena where he leads the effort to understand immunogenicity risk associated with biotherapeutics.

Mark Fogg, Ph.D., leads the Immunology Group at Abzena, a company that enables the development and manufacture of better biopharmaceuticals. Mark obtained his PhD in T cell immunology at the University of Reading, and carried out his postdoctoral work on the generation of T cells for cancer immunotherapy at Harvard Medical School. He then migrated to industry to lead a cell biomarker discovery group within Pfizer BioTX R&D prior to joining Abzena where he leads the effort to understand immunogenicity risk associated with biotherapeutics.